

CARDIOGENESIS CORP /CA

Form 8-K

May 21, 2008

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 19, 2008

CARDIOGENESIS CORPORATION

(Exact name of registrant as specified in its charter)

California

000-28288

77-0223740

*(State or other jurisdiction of
incorporation)*

(Commission File Number)

*(IRS Employer
Identification No.)*

11 Musick
Irvine, CA 92618

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (949) 420-1800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 8.01 Other Events.

SIGNATURE

Table of Contents

Item 8.01 Other Events.

On May 19, 2008, Cardiogenesis Corporation (the Company) held its annual meeting of shareholders. At the meeting, the shareholders elected to the Board of Directors the following six persons, each of whom was a director of the Company prior to the annual meeting:

Gary S. Allen

Paul J. McCormick

Robert L. Mortensen

Ann T. Sabahat

Marvin J. Slepian

Gregory D. Waller

In addition, the shareholders ratified the selection of KMJ Corbin & Company LLP as the Company's independent auditors for fiscal 2008.

Following the annual meeting, the Board of Directors of the Company modified the director compensation policy to clarify that directors who attend scheduled Board meetings telephonically will be entitled to receive a fee of \$1,250 per each regularly scheduled meeting (as opposed to the \$2,500 per regularly scheduled meeting fee that directors are entitled to receive in connection with meetings attended in person).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARDIOGENESIS CORPORATION
(Registrant)

Date: May 21, 2008

By: /s/ William Abbott
William Abbott,
Chief Financial Officer